Business
MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.
Potential merger to create new industry leader. Vancouver, British Columbia--(Newsfile Corp. - O...
About this update from Mynd Life Sciences Inc
[{"type":"text","content":"MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.Potential merger to create new industry leader.Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) (\"MYND\" or the \"Company\"), a pioneering biopharmaceutical research and development company dedicated to revolutionizing treatments for patients battling relentless neurological and inflammatory diseases, announces that it has taken a definitive step forward by entering into a non-binding letter of intent (\"LOI\") with Cava Healthcare Inc (CAVA) to merge these two industry leaders to form a powerful new commercial entity. MYND already shares a robust business relationship with CAVA, particularly concerning their patents in two pivotal areas. This strategic merger is poised to redefine the landscape of medical innovation and is a testament to the unwavering commitment of both companies to drive transformative advancements in healthcare.The proposed merger will be preceded by independent third-party valuations of both companies. Arrangements within each company will be negotiated by subcommittees of unconflicted Directors from both CAVA and MYND and it will require affirmative votes by the Boards of Directors of both companies. Cava brings a portfolio of over 40 patents, licenses and patent applications that can be separated into nine families: (1) Potential new methods to treat Alzheimer's disease and related diseases, (2) Potential new methods to diagnose Alzheimer's disease and related diseases, (3) Potential new methods to treat cancer with recombinant cytokines, (4) Potential new methods to treat cancer with cell-based therapies, (5) Potential new methods to treat cancer with small molecules, (6) Potential new methods to predict cancer outcome (prognosticators), (7) Potential new methods to screen for anti-cancer agents, (8) Potential new methods to screen for immune enhancing agents, and (9) The creation and use of synthetic curcuminoids to treat cancer. The integration of CAVA Healthcare's extensive portfolio of patents with MYND's scientific expertise represents a monumental opportunity for groundbreaking advancements in medical technology. MYND's seasoned scientific team, with their deep knowledge and innovative approach, is anticipated to be the driving force behind the...